Phase 1 Cutaneous Melanoma Clinical Trials
8 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–8 of 8 trials
Recruiting
Phase 1
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
Advanced Solid TumorCutaneous MelanomaUveal Melanoma, Metastatic
MonTa Biosciences ApS106 enrolled5 locationsNCT04855435
Recruiting
Phase 1Phase 2
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Advanced Solid TumorMetastatic CancerCutaneous Melanoma
Aulos Bioscience, Inc.159 enrolled17 locationsNCT05267626
Recruiting
Phase 1Phase 2
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Cutaneous MelanomaMetastatic Uveal Melanoma
IDEAYA Biosciences336 enrolled15 locationsNCT03947385
Recruiting
Phase 1
ACTengine® IMA203 Combined With mRNA-4203
Cutaneous MelanomaSynovial Sarcoma
Immatics US, Inc.15 enrolled4 locationsNCT06946225
Recruiting
Phase 1Phase 2
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
Cutaneous MelanomaBrain Metastases
University of Utah33 enrolled2 locationsNCT06194929
Recruiting
Phase 1Phase 2
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
CancerCutaneous MelanomaMelanoma Stage IV+1 more
Krystal Biotech, Inc.240 enrolled15 locationsNCT05970497
Recruiting
Phase 1Phase 2
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Solid Tumor, AdultCutaneous MelanomaRefractory Cancer+3 more
GV20 Therapeutics365 enrolled13 locationsNCT05669430
Recruiting
Phase 1Phase 2
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Advanced Solid TumorCancerNon-small Cell Lung Cancer+4 more
OncoResponse, Inc.168 enrolled4 locationsNCT06090266